In vitro bactericidal activities of two novel dihydropyridine derivatives against Mycobacterium tuberculosis

  • Mehdi Zandhaghighi Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Farzin Hadizadeh School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  • Saman Soleimanpour Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Zahra Meshkat Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Seyed Abdolrahim Rezaee Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Mohammad Derakhshan Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  • Kiarash Ghazvini Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: Introducing new and effective antitubercular agents is important in tuberculosis control programs. In this study, the in vitro antitubercular activity of two novel 1,4-dihydropyridine derivatives (F-27, Cl-33) were screened against a total of 113 different strains of Mycobacterium tuberculosis (77 susceptible and 36 resistant clinical isolates).


Methodology: The in vitro activities of these compounds were evaluated based on the modified broth macro-dilution assay.


Results: Compound F-27 showed more than 90% growth inhibition at the range of 2 to 8 μg/mL (minimum inhibitory concentration [MIC]90: 4.13 ± 0.45 µg/mL; p  < 0.01), and complete growth inhibition was observed at the range of 8 to 32 μg/mL (minimum bactericidal concentration [MBC]: 11.2 ± 1.65 µg/mL; p < 0.01) against susceptible strains. However, 92% of the resistant strains showed some degree of susceptibility against this compound (MIC90 range: 16 to 64 µg/mL; mean: 40.4 ± 8 µg/mL; p < 0.01). It was found that although there is a linear relationship between the inhibitory activity of F-27 and isoniazid against resistant strains at low concentrations (r = 0.484, p < 0.001), there was no relationship between resistance to isoniazid and F-27 at higher concentrations (r = 0.019, p > 0.1). This may emphasize no cross-resistance between F-27 and isoniazid.


Conclusions: Considering the sufficient sample size of the study and based on the excellent antimycobacterial activity of F-27, it could be concluded that F-27 is a potent candidate as a lead compound, and may be considered for development of a new antitubercular agent.

Published
2017-06-27
How to Cite
Zandhaghighi M, Hadizadeh F, Soleimanpour S, Meshkat Z, Rezaee S, Derakhshan M, Ghazvini K (2017) In vitro bactericidal activities of two novel dihydropyridine derivatives against Mycobacterium tuberculosis. The Journal Of Infection In Developing Countries 11 (06): 453-458. https://doi.org/10.3855/jidc.7966
Section
Original Articles

Keywords

Drug discovery; dihydropyridines; antitubercular agents; drug evaluation, preclinical